Towards Healthcare
Drug-Eluting Balloon Catheters Market to Rise at 11.1% CAGR till 2034

Drug-Eluting Balloon Catheters Market 2025 Innovations and Growth Scope

According to market projections, the global drug-eluting balloon catheters market, valued at USD 1.42 billion in 2024, is anticipated to reach USD 4.02 billion by 2034, growing at a CAGR of 11.1% over the next decade. The increasing cases of cardiovascular diseases and peripheral artery disease (PAD) are driving the global market. A rise in demand for minimally invasive procedures is fueling the expansion of North America’s market.

Content

  • Last Updated: 25 September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The drug-eluting balloon catheters market is worth USD 1.58 billion in 2025, and by 2034, it is forecasted to hit USD 4.02 billion, registering a CAGR of 11.1% over the decade.

North America is currently leading the drug-eluting balloon catheters market due to the growing prevalence of cardiovascular diseases (CVDs), especially coronary artery disease and peripheral artery disease (PAD).

Some key players include Abbott, B. Braun Melsungen AG, Bard/BD Interventional, BIOTRONIK, and Boston Scientific.

The advantages of using DEB are no stent remains behind, reduced inflammation, shorter dual antiplatelet therapy (DAPT), and homogeneous drug delivery.

DEBs are used for AV fistulas due to their high re-blockage rate, improved potency, and reduced maintenance procedures.

NIH, US FDA, ClinicalTrials.gov, GOV.UK, CDC, MedlinePlus.gov, WHO.
Any Questions